**Core Concept:** Acute anterior uveitis is an inflammation of the uvea, the middle layer of the eye that contains blood vessels and produces the iris. It can be caused by various factors including infections, autoimmune disorders, or post-operative complications. Inflammation in the eye can lead to increased intraocular pressure (IOP) and potentially cause damage to the optic nerve and vision loss.

**Why the Correct Answer is Right:** The drug of choice for increased IOP in acute anterior uveitis is **D** (Dorzolamide hydrochloride). Dorzolamide is a carbonic anhydrase inhibitor, which reduces aqueous humor production in the eye by inhibiting the enzyme carbonic anhydrase. By decreasing aqueous humor production, IOP is lowered and helps protect the eye from further damage.

**Why Each Wrong Option is Incorrect:**

A. **Option A (Brinzolamide)** is also a carbonic anhydrase inhibitor, but it has a slower onset of action and may not be as effective in acute situations where IOP needs to be lowered promptly.
B. **Option B (Timolol)** is a beta-blocker, which is not targeted at reducing aqueous humor production. Beta-blockers are used for hypertension or angina but not specifically for IOP management in uveitis.
C. **Option C (Alpha Blockers)** are used to treat glaucoma or ocular hypertension but not for uveitis-induced IOP elevation. They work by blocking alpha receptors on the trabecular meshwork, increasing outflow of aqueous humor, and lowering IOP. Since acute anterior uveitis causes increased IOP due to inflammation and not primarily due to reduced outflow, alpha-blockers are not the appropriate choice.

**Clinical Pearl:** In cases of acute anterior uveitis, prompt management of increased IOP is crucial to prevent optic nerve damage and vision loss. While carbonic anhydrase inhibitors like Dorzolamide and Brinzolamide are used for chronic glaucoma management, Dorzolamide is a more suitable choice for acute situations due to its faster onset of action.

**Correct Answer Explanation:**

Dorzolamide hydrochloride (Corneal block) is a carbonic anhydrase inhibitor, which is a faster acting medication compared to Brinzolamide (Azopt) and is more suitable for acute situations. Dorzolamide works by inhibiting carbonic anhydrase, reducing aqueous humor production, and decreasing intraocular pressure (IOP). In acute anterior uveitis, IOP elevation is due to inflammation and not primarily caused by reduced outflow, making Dorzolamide the preferred choice.